Abstract: Background and Aims: Phenylalanine-restricted diets have proven effective in treating phenylketonuria. However,
such diets have occasionally been reported to hinder normal development. Our study aimed to assess whether
treating 0–4-year-old phenylketonuric patients with 6R-tetrahydrobiopterin might prevent growth retardation
later in life.
Methods: We conducted a longitudinal retrospective study which examined anthropometric characteristics of
phenylketonuric patients on 6R-tetrahydrobiopterin therapy (22 subjects), and compared them with a group of
phenylketonuric patients on protein-restricted diets (44 subjects). Nutritional issues were also considered.We further
explored possible relationships betweenmutations in the PAH gene, BH4 responsiveness and growth outcome.
Results: No significant growth improvements were observed in either the group on 6R-tetrahydrobiopterin treatment
(height Z-score: initial = -0.57 ± 1.54; final = -0.52 ± 1.29; BMI Z-score: initial = 0.17 ± 1.05;
final = 0.18 ± 1.00) or the diet-only group (height Z-score: initial = -0.92 ± 0.96; final = -0.78 ± 1.08; BMI
Z-score: initial =0.17 ± 0.97; final = -0.07 ± 1.03) over the 1-year observation period. Furthermore, we found
no significant differences (p N 0.05) between the two groups at any of the time points considered (0, 6 and
12 months). Patients on 6R-tetrahydrobiopterin increased their phenylalanine intake (from 49.1 [25.6–60.3] to
56.5 [39.8–68.3] mg kg-1 day-1) and natural protein intake (from 1.0 [0.8–1.7] to 1.5 [1.0–1.8] g kg-1 day-1),
and some patientsmanaged to adopt normal diets.Higher phenylalanine and natural protein intakeswere positively
correlated with better physical outcomes in the diet-only group (p b 0.05). No correlation was found between
patient genotype and physical outcomes, results being similar regardless of the nutritional approach used.We did not detect any side effects due to 6R-tetrahydrobiopterin administration.
Conclusions: Our study indicates that treating 0–4-year-old phenylketonuric patientswith 6R-tetrahydrobiopterin is
safe. However, poor developmental outcomes were observed, despite increasing the intake of natural proteins.
Genotype could be a valid predictor of tetrahydrobiopterin-responsiveness, since patients who carried the same
genotype responded similarly to the 6R-tetrahydrobiopterin loading test. On the other hand, harbouring 6Rtetrahydrobiopterin
responsive genotypes did not predispose patients to better physical outcomes.
Other publications of the same journal or congress with authors from the University of Cantabria